MedTrace Logo

Combination of Basiliximab and Pegaspargase in the Treatment of ENKTCL

NCT04337593 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2020-04-07

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy and safety of Basiliximab in combination with pegaspargase in the treatment of relapsed/refractory NK/T-cell lymphoma.

Conditions

  • Extranodal NK/T-cell Lymphoma

Interventions

DRUG

Basiliximab

20mg d1,8, repeated every 3 weeks

DRUG

Pegaspargase

2500IU/㎡, d1,repeated every 3 weeks

Sponsors & Collaborators

  • Beijing Tongren Hospital

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-01
Primary Completion
2022-05-31
Completion
2022-12-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04337593 on ClinicalTrials.gov